Purpose-built semiconductor chips for next-gen neural implants
Enable minimally invasive neural implants for epilepsy patients; Support wireless intracranial neuromonitoring for drug-resistant epilepsy; Power stimulation systems for Parkinson’s disease; Facilitate brain-computer interfaces for research applications; Enable scalable neuromodulation for dementia treatment
Secured £1M investment in 2024; Won three UK Government ARIA Awards; Named ChipStart Company of the Year; Secured £1.4M collaborative grant for epilepsy research; Partnerships with Imperial College London and Innovate UK